Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 16/20 | 0.61 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20220613 | 1.00 | ADRA1A (0.61) | ADRA1ADGAT2TMEM97SIGMAR1 | |
| SCHEMBL20312054 | 0.88 | ADRA1A (0.61) | ADRA1ADGAT2 | |
| SCHEMBL20220518 | 0.87 | ADRA1A (0.80) | ADRA1ATMEM97SIGMAR1 | |
| SCHEMBL16824536 | 0.87 | ADRA1A (0.80) | ADRA1ATMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL18186152 | 0.86 | ADRA1A (0.78) | ADRA1ATMEM97SIGMAR1 | |
| SCHEMBL18744229 | 0.81 | ADRA1A (0.66) | ADRA1A | |
| SCHEMBL16846262 | 0.76 | ADRA1A (1.00) | ADRA1A | |
| SCHEMBL30823772 | 0.75 | PRMT5 (0.53) | ADRA1A | |
| SCHEMBL22418693 | 0.75 | PRMT5 (0.53) | ADRA1A | |
| SCHEMBL20052796 | 0.74 | ADRA1A (0.79) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-30 | — | — | US | disclosed |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | disclosed |
| EP-3083592-B1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS | Bayer Pharma AG (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3083592-B1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS | Bayer Pharma AG (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3329920-A2 | ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-06 | — | — | EP | disclosed |
| EP-3329920-A2 | ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-9944621-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-17 | — | — | US | disclosed |
| US-9944621-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-17 | — | — | US | disclosed |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| WO-2015091414-A2 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885DGAT2 3853/4885TMEM97 2707/4885 |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 1852/4885DGAT2 3968/4885TMEM97 2319/4885 |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885DGAT2 3853/4885TMEM97 2707/4885 |
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885DGAT2 3853/4885TMEM97 2707/4885 |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885DGAT2 3853/4885TMEM97 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.